COR — Cencora, Inc.

Cencora Inc. Q3 Fiscal Year 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $84.8 billion, up 5% year-over-year.
• Adjusted Operating Income: $1.2 billion, a 17% increase.
• Adjusted EPS: Grew 12% to $17.75-$17.95; guidance raised from $17.70-$17.90.
• Gross Profit: $3.5 billion, up 23%, with a gross profit margin of 4.16%.
• Operating Expenses: Increased 27% to $2.3 billion, primarily due to the OneOncology acquisition.
• Net Interest Expense: $141 million, up $59 million due to debt from the OneOncology acquisition.
• Free Cash Flow: Year-to-date adjusted free cash flow of $1.1 billion, with full-year guidance unchanged at approximately $3 billion.

2. Strategic Updates and Business Highlights

• Specialty Pharmaceutical Platform: Cencora's focus on specialty pharmaceuticals is driving growth, particularly in oncology and retina practices.
• Digital Transformation: Investments in AI for demand forecasting are enhancing operational efficiency and service reliability.
• Management Services Organizations (MSOs): Strong performance from OneOncology and RCA, with plans to continue integrating and expanding these platforms.
• Talent and Culture: New leadership appointments, including CFO Eva Boratto, are expected to strengthen execution and strategic focus.

3. Forward Guidance and Outlook

• Fiscal 2026 Guidance: Adjusted EPS guidance raised to $17.75-$17.95; operating income growth expected to be 13%-14%.
• U.S. Healthcare Solutions Revenue Growth: Anticipated to be in the lower half of the 4%-6% range.
• International Healthcare Solutions Revenue Growth: Expected to be around 8% at the low end of the previous range.
• Continued Investment: Focus on tuck-in acquisitions in the MSO space and maintaining capital deployment strategies that include share repurchases and dividends.

4. Bad News, Challenges, or Points of Concern

• Increased Operating Expenses: Significant rise in operating expenses due to acquisitions, which could pressure margins.
• Market Dynamics: Manufacturer list price reductions and the loss of an oncology customer have created revenue headwinds.
• Interest Expense: Rising net interest expense due to debt financing could impact profitability.
• Regulatory Risks: Potential changes in ASP rules and 340B program dynamics could pose risks to reimbursement and profitability.
• Competitive Pressures: Increased competition in the specialty logistics and 3PL markets may affect market share and pricing.

5. Notable Q&A Insights

• Reacceleration in U.S. Pharma Business: Management noted a strong rebound in U.S. Healthcare Solutions, particularly in specialty segments, with OneOncology outperforming expectations.
• Clinical Trials and Research Opportunities: There is significant growth potential in clinical trial support, especially for OneOncology, which is still in the early stages of development.
• 340B Program Impact: Management is closely monitoring changes in the 340B program but remains confident that any regulatory changes will not negatively impact physician reimbursement.
• Customer Portfolio Health: Management expressed satisfaction with their diverse customer base and relationships, indicating no significant concerns regarding renewals or customer transitions.

Overall, Cencora reported strong financial results driven by its specialty pharmaceutical strategy, while also navigating challenges related to increased expenses and market dynamics. The company remains optimistic about its growth trajectory and strategic initiatives moving forward.